Commentary|Podcasts|August 25, 2023
ESG Evolution
Author(s)Nicholas Saraceno, Senior Editor
In this PC Podcast episode, Susanne Katus discusses the increasing number of regulations impacting both pharma and biotech companies.
Advertisement
In this exclusive PC Podcast interview, Susanne Katus, SVP, market leader, corporate secretary at Datamaran, a platform that monitors and analyzes risk factors, dives into:
- The growing number of environmental, social, and governance (ESG) regulations impacting these aforementioned businesses
- Where the responsibility lies for them in terms of ESG compliance
- What can be done in order for these corporations to be ahead of the game
- Why ESG should be a top priority
The latest episode of The Pharmaceutical Commerce Podcast is available directly on SoundCloud.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How Specialty Growth and Cold Chain Demand Are Rewriting Distribution Strategy
2
Why Geopolitical Supply Chain Mapping Is Critical for Life Sciences
3
Commercial Trade's Expanding Mandate: From Product Movement to Commercial Performance
4
Pharma Pulse: Cardinal Health Bulks Up Home Care, Trump Unveils Phased Generics Tariffs
5